Eirgenix Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Trastuzumab Biosimilar Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers

EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of patients with HER2-positive (HER2+) breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the European Union.

United statesGiovanni cancemiEuropean commissionNational health insurance administrationEuropean unionEirgenix incMinistry of healthImage creditRgenix incTaiwan foodDrug administration

EG12014 Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers

EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union for the treatment of patients with HER2-positive breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the EU.

United statesEirgenix incMinistry of healthEuropean unionEuropean commissionNational health insurance administrationRgenix incTaiwan foodDrug administrationHer2 positiveTrastuzumab biosimilar

EirGenix s Breast Cancer Biosimilar Receives Marketing Authorization by EC

/PRNewswire/ EirGenix Inc. (6589. TT) announced today that its trastuzumab biosimilar medicine (EG12014) which their commercial partner Sandoz plans to.

T ai peiMinistry of healthEirgenix incEuropean commissionPrnewswire eirgenix incNational health insurance administrationHealth care amp hospitalsMedical pharmaceuticalsInternational medical approval

EirGenix s Breast Cancer Biosimilar Receives Marketing Authorization by EC – Padovanews

EirGenix s Breast Cancer Biosimilar Receives Marketing Authorization by EC – Padovanews
padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.

T ai peiNational health insurance administrationEirgenix incEuropean commissionMinistry of health

Gemigliptin Market is Likely to Reach US$ 2 59 Billion by 2030, expanding at Over 5 4% CAGR: Coherent Market Insights |

Gemigliptin Market is Likely to Reach US$ 2 59 Billion by 2030, expanding at Over 5 4% CAGR: Coherent Market Insights |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited kingdomUnited statesSouth koreanGl pharma gmbHanall biopharmaGemigliptin monotherapyInternational diabetes federationSandoz international gmbDaewoong pharmaceutical co ltdLife sciencesWorld health organizationHuons co ltdDonga st co ltdPorters five forces analysisHanmi pharmaceutical co ltd